Core Viewpoint - BellRing Brands, Inc. (BRBR) is facing a securities class action lawsuit alleging that the company and its executives misled investors about the true drivers of its sales growth, which resulted in a significant loss of market value estimated at $2.9 billion [1][2][4]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that BellRing's sales growth in 2025 was artificially inflated due to retailers hoarding inventory to avoid stock shortages, rather than genuine consumer demand [2][4]. - Following the revelation of these practices, BellRing's share price experienced a dramatic decline, including a 33% drop in a single day after disappointing financial results were announced [2][4]. - The complaint asserts that the reported sales figures did not accurately reflect end-consumer demand but were instead a result of temporary inventory stockpiling by key customers [4]. Group 2: Financial Performance and Market Reaction - On August 4, 2025, BellRing reported a narrowed sales outlook, attributing the disappointing results to increased competition and a mismatch between consumption and shipments, which led to a $17.46 drop in share price [4]. - The CFO of BellRing acknowledged that some retailers had been hoarding inventory, which contributed to the misleading sales figures, yet downplayed the potential negative impact on consumption [4]. - The lawsuit highlights that once retailers felt confident that product shortages were resolved, they began to destock their inventory, further impacting BellRing's sales negatively [4].

Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics (NKTR) on behalf of shareholders who acquired securities between February 26, 2025, and December 15, 2025, due to alleged securities fraud [1]. Group 1: Lawsuit Details - The lawsuit claims that Nektar made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period [4]. - Specifically, it is alleged that the enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and protocols, which negatively impacted the trial's results [4]. - Following the announcement of the trial's failure to reach statistical significance on December 16, 2025, Nektar's stock price dropped by $4.14, or 7.8%, closing at $49.16 per share [3]. Group 2: Shareholder Actions - Shareholders who suffered losses on their Nektar investments are encouraged to inquire about participating in the ongoing securities fraud lawsuit [2]. - The deadline for filing a lead plaintiff motion is set for May 5, 2026 [1].

Law Offices of Frank R. Cruz Encourages Driven Brands Holdings Inc. (DRVN) Shareholders To Inquire About Securities Fraud Class Action Mar 16, 2026 12:07 PM Eastern Daylight Time IF YOU SUFFERED A LOSS ON YOUR DRIVEN BRANDS HOLDINGS INC. (DRVN) INVESTMENTS, CLICK HERETO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, ...

Core Viewpoint - A class action lawsuit has been filed against ODDITY Tech Ltd. and certain officers for alleged violations of federal securities laws during the Class Period from February 26, 2025, to February 24, 2026 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [3]. - Specific allegations include that an algorithm change by the company's largest advertising partner led to advertisements being diverted to lower-quality auctions at abnormally high costs, significantly increasing customer acquisition costs [3]. - As a result of these issues, the defendants allegedly overstated the strength and sustainability of the company's digital operating model and market position, rendering their public statements materially false and misleading [3]. Group 2: Legal Process and Participation - Investors who purchased Oddity securities during the Class Period are encouraged to join the lawsuit, with a deadline of May 11, 2026, to request appointment as lead plaintiff [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if successful in the lawsuit [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6]. - The firm's focus is on restoring investor capital and ensuring corporate accountability to maintain market integrity [6].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the class period from June 16, 2025, to January 8, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or acquired Aquestive Therapeutics securities during the specified class period [2]. - The complaint alleges that the defendants made materially false and misleading statements regarding the approval timeline and launch of the New Drug Application for Anaphylm (dibutepinephrine) sublingual film [3]. - Specific allegations include overstating the approval timeline, lacking a reasonable basis for confidence in the NDA submission, and concealing significant risks related to human factors associated with the product [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit have until May 4, 2026, to request appointment as lead plaintiff, although sharing in any recovery does not require serving as lead plaintiff [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - A class action lawsuit has been filed against Navan, Inc. for allegedly misleading investors during its IPO by not disclosing significant increases in sales and marketing expenses, leading to a substantial decline in share value since the offering [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired Navan shares from October 28, 2025, to February 23, 2026, including during the IPO [1][2]. - Investors have until April 24, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Financial Impact - Navan's shares have dropped significantly, trading as low as $9.01 per share, representing a loss of over 60% from the IPO offering price [3]. Group 3: Company Overview - Navan, headquartered in Palo Alto, California, specializes in booking and expense reporting software for business travelers, aimed at streamlining travel and expense management for companies [2]. Group 4: Law Firm Background - Berger Montague is a prominent law firm with a focus on complex civil litigation and class actions, having recovered over $50 billion for clients over its 55-year history [4].

Core Viewpoint - Driven Brands Holdings Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial misstatements impacting investors [1][3][4]. Group 1: Class Action Details - The class action lawsuit is titled Clark v. Driven Brands Holdings Inc., and it includes claims against the company and certain executives for making false or misleading statements during the class period from May 9, 2023, to February 24, 2026 [1][3]. - Investors who suffered substantial losses during the class period have until May 8, 2026, to seek appointment as lead plaintiff [1][5]. Group 2: Allegations of Financial Misstatements - The lawsuit alleges that Driven Brands made errors in recording leases, which affected right of use assets and liabilities on the balance sheet as of December 28, 2024, and September 27, 2025 [3]. - There were also reported inaccuracies in cash balances and operating cash flows, leading to overstatements of cash and revenue, and understatements of selling, general, and administrative expenses for fiscal years 2023 and 2024 [3]. - Additional allegations include misclassification of expenses and errors related to income tax provisions and revenue recognition, particularly in the ATI business for fiscal year 2025 [3][4]. Group 3: Impact of Disclosure - On February 25, 2026, Driven Brands disclosed material errors in its previously issued financial statements for fiscal years 2023 and 2024, leading to a nearly 40% drop in the stock price [4].

Core Viewpoint - Soleno Therapeutics Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to the safety and commercial viability of its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [1][4]. Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its only commercial product being diazoxide choline extended-release tablets (DCCR) [3]. Allegations of the Class Action Lawsuit - The lawsuit claims that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [4]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [4]. - A critical report by Scorpion Capital LLC raised concerns about DCCR, leading to a nearly 12% decline in Soleno's stock price over two trading days [5]. - Following the report, a patient death linked to DCCR was disclosed, resulting in a further approximately 19% decline in stock price [6]. - The financial results for Q3 2025 indicated a disruption in DCCR's launch trajectory, with a reported 27% decline in stock price after the announcement [7]. Legal Process - Investors who purchased Soleno common stock during the class period have until May 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1][8]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [9]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [10].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its studies on setrusumab for Osteogenesis Imperfecta, leading to a significant drop in share price [1][3]. Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focusing on treatments for rare diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased Ultragenyx common stock from August 3, 2023, to December 26, 2025, with a deadline of April 6, 2026, for potential lead plaintiff representatives [1][2]. - The complaint alleges that Ultragenyx raised investor expectations about the ORBIT and COSMIC studies while concealing that these studies did not significantly reduce clinical fracture rates compared to control groups [3]. Financial Impact - Following the disclosure of the study results, Ultragenyx's share price fell from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, representing a loss of over 42% in a single day [3].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Graphic Packaging Holdings Company, focusing on possible mismanagement and breaches of fiduciary duties by the board of directors following executive changes [1][3]. Group 1: Investigation Details - The investigation is prompted by a shareholder holding 4.2% of the Company's stock, who expressed concerns after the announcement of Michael Doss's replacement as CEO by Robbert E. Rietbroek [3]. - The investigation also follows the recent departure of the Executive Vice President and General Counsel shortly after the CEO transition [3]. Group 2: Legal Representation - The Portnoy Law Firm is encouraging investors to contact them for a complimentary case evaluation and to discuss options for pursuing claims to recover losses [2][4]. - The firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].